Related Experiment Video
Updated: May 23, 2025
Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
Published on: September 21, 2017
piRNA28846 has the potential to be a novel RNA nucleic acid drug for ovarian cancer
Hong-Lei Qin1, Yang Han1, Jian-Qi Li1
1Department of Obstetrics and Gynecology, Department of Gynecologic Oncology Research Office, Guangzhou Key Laboratory of Targeted Therapy for Gynecologic Oncology, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Abstract:
Conventional targeted therapies primarily rely on small molecules and proteins. However, they often struggle to enter specific protein conformations, which limits their therapeutic effectiveness. In contrast, RNA therapy is emerging as a more precise and effective targeting strategy. Through differential analysis comparing Pandora-Seq data with clinical samples, we discovered that the small RNA piR-28846 naturally, occurring in human body, exhibited low expression levels in ovarian cancer tissues. Experimental results indicate that piR-28846 inhibits the growth of ovarian cancer cells. Additionally, piR-28846 demonstrated significant therapeutic effects in xenograft models and ovarian cancer-like organoids. Further studies revealed that piR-28846 binds to NSUN2 and down-regulates it, which in turn affects the stability of KPNA2 mRNA. Notably, KPNA2 negatively regulates NSUN2 expression and localization. Given its inhibitory effects observed in vivo, in vitro, and in the ovarian cancer organoid model, we believe piR-28846 has strong potential as a small nucleic acid therapy of ovarian cancer.
Insights
Small RNA piR-28846 shows promise as an ovarian cancer therapy. This naturally occurring molecule inhibits tumor growth by down-regulating NSUN2 and affecting KPNA2 mRNA stability.
Area of Science:
- Oncology
- Molecular Biology
- RNA Therapeutics
Background:
- Conventional targeted therapies face limitations in achieving specific protein conformations.
- RNA therapy offers a precise and effective alternative for targeted treatments.
- Ovarian cancer remains a significant health challenge with ongoing needs for novel therapeutic strategies.
Purpose of the Study:
- To investigate the therapeutic potential of naturally occurring small RNAs in ovarian cancer.
- To identify specific small RNAs that are underexpressed in ovarian cancer tissues.
- To elucidate the molecular mechanisms underlying the anti-cancer effects of identified small RNAs.
Main Methods:
- Differential expression analysis of small RNAs using Pandora-Seq data and clinical samples.
- In vitro experiments assessing the impact of piR-28846 on ovarian cancer cell growth.
- In vivo studies using xenograft models and organoid cultures to evaluate therapeutic efficacy.
- Molecular mechanism studies involving RNA-protein interactions and mRNA stability analysis.
Main Results:
- The small RNA piR-28846 was found to be underexpressed in ovarian cancer tissues.
- piR-28846 demonstrated significant inhibition of ovarian cancer cell proliferation in vitro.
- Therapeutic effects of piR-28846 were confirmed in xenograft models and ovarian cancer organoids.
- piR-28846 was shown to bind and down-regulate NSUN2, impacting KPNA2 mRNA stability.
Conclusions:
- piR-28846 exhibits potent anti-ovarian cancer activity through a novel molecular pathway.
- The piR-28846/NSUN2/KPNA2 axis represents a potential therapeutic target for ovarian cancer.
- piR-28846 holds significant promise as a novel small nucleic acid-based therapy for ovarian cancer.
More Related Videos
Related Concept Videos
02:57piRNA - Piwi-interacting RNAs
02:15Experimental RNAi
02:55The Nucleolus
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...